Global Information
회사소개 | 문의 | 비교리스트

저항성 고혈압 : 파이프라인 리뷰

Resistant Hypertension - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 410972
페이지 정보 영문 34 Pages
가격
US $ 2,000 ₩ 2,417,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,834,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,251,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


저항성 고혈압 : 파이프라인 리뷰 Resistant Hypertension - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 34 Pages

저항성 고혈압은 항고혈압제로 치료되고 있음에도 불구하고, 고혈압을 컨트롤 할 수 없는 상태를 가리킵니다. 저항성 고혈압의 원인에는 혈압을 컨트롤하고 있는 호르몬의 이상, 동맥을 막히게 하는 혈소판의 증착, 비만 및 수면 장애 등이 있습니다. 이것은 라이프스타일의 재검토와 정기적인 의약품의 복용으로 대처할 수 있습니다.

저항성 고혈압(Resistant Hypertension) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

저항성 고혈압 개요

  • 파이프라인 제품 : 개요

기업에서 개발중인 치료제

파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 개발에 참여하고 있는 기업

  • Bayer AG
  • Novartis AG
  • Sarfez Pharmaceuticals Inc
  • PhaseBio Pharmaceuticals Inc
  • Zumbro Discovery Inc

치료제 평가

  • 단독치료 제품별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

  • BAY-1636183
  • LHW-090
  • PB-1120
  • SP-20203
  • ZD-100

휴지중인 프로젝트

개발이 중지된 제품

부록

도표

KSM 17.01.19

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant Hypertension - Pipeline Review, H2 2016, provides an overview of the Resistant Hypertension (Cardiovascular) pipeline landscape.

Resistant hypertension is defined as high blood pressure that remains uncontrolled despite treatment with antihypertensive agents. Causes of resistant hypertension include abnormalities in the hormones that control blood pressure, accumulation of artery-clogging plaque in blood vessels, obesity and sleep problems. This is handled by lifestyle alterations and regular medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Resistant Hypertension - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Resistant Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Resistant Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Resistant Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively.

Resistant Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Resistant Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Resistant Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Resistant Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Resistant Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Resistant Hypertension (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Resistant Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Resistant Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Resistant Hypertension Overview
    • Pipeline Products for Resistant Hypertension - Overview
  • Resistant Hypertension - Therapeutics under Development by Companies
  • Resistant Hypertension - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Resistant Hypertension - Products under Development by Companies
  • Resistant Hypertension - Companies Involved in Therapeutics Development
    • Bayer AG
    • Novartis AG
    • Sarfez Pharmaceuticals Inc
    • PhaseBio Pharmaceuticals Inc
    • Zumbro Discovery Inc
  • Resistant Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BAY-1636183 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LHW-090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-1120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-20203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZD-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Resistant Hypertension - Dormant Projects
  • Resistant Hypertension - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Resistant Hypertension, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Resistant Hypertension - Pipeline by Bayer AG, H2 2016
  • Resistant Hypertension - Pipeline by Novartis AG, H2 2016
  • Resistant Hypertension - Pipeline by Sarfez Pharmaceuticals Inc, H2 2016
  • Resistant Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016
  • Resistant Hypertension - Pipeline by Zumbro Discovery Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Resistant Hypertension - Dormant Projects, H2 2016
  • Resistant Hypertension - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Resistant Hypertension, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q